Daniel Pereira
Chief Scientific Officer CrossBridge Bio
Daniel Pereira is Chief Scientific Officer at CrossBridge Bio, bringing over 25 years of experience in oncology biologics drug discovery and development across biotech and pharmaceutical organizations. Prior to CrossBridge Bio, Daniel held Chief Scientific Officer roles at Invenra and Arch Oncology, where he led the development of bispecific antibodies and next-generation immuno-oncology therapeutics. Earlier in his career, he held senior leadership positions at Agensys (Astellas), Roche/Arius, and ImClone Systems, overseeing antibody-based drug discovery programs. He holds a PhD from McMaster University and has authored numerous publications and patents in oncology and biologics research.
Seminars
Thursday 10th September 2026
Reflecting on the First Attempts with Novel Payloads, & What we are Doing Differently Now
8:45 am
- What is the path to success for novel payloads, including how to navigate early assessment of payload platforms?
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success?
- Discussing the panellists’ approach to business development. What would a win/ win business deal look like that focuses on payloads?
